2025/12/02 by Yongkang Wu, Yankun Zhang, Xiaojia Shi +13 · 1 voice · 1 citation
Medicine · Immunology and Microbiology · #Ferroptosis and cancer prognosis #Cancer, Stress, Anesthesia, and Immune Response #Immune cells in cancer
paper · pdf · doi:10.1172/jci195685
openalex publication_date 2025/12/02 · openalex created_date 2025/12/03 · openalex updated_date 2026/06/21
Emerging evidence demonstrates that chronic stress alters immunological, neurochemical, and endocrinological functions, thereby promoting tumor progression. However, the underlying metabolic mechanism of chronic stress in tumor progression is still elusive. Using multiomics analysis, we found that aminopeptidase N (ANPEP) was upregulated in tumors with chronic restraint, associating with the reprogramming of amino acid metabolism. Functional assays revealed that ANPEP promoted liver cancer growth and metastasis. Knockdown of ANPEP blocked chronic stress-induced liver cancer progression. Chronic stress-induced glucocorticoids promoted nuclear receptor subfamily 3 group C member 1 nuclear translocation to activate ANPEP transcription by directly binding to its promoter. Furthermore, ANPEP promotes glutathione synthesis, subsequently inhibiting ROS-induced ferroptosis. Mechanistically, ANPEP interacted with solute carrier family 3 member 2 (SLC3A2) to block membrane associated ring-CH-type finger 8-mediated lysosome-dependent degradation of SLC3A2, promoting intracellular l-cystine transport, thereby increasing glutathione synthesis. The combination of ANPEP silencing and sorafenib treatment showed a synergistic effect in inhibiting liver cancer progression. Finally, clinical data and mouse models demonstrated that chronic stress drove liver tumor progression via ANPEP-regulated SLC3A2. These findings reveal unanticipated communication between chronic stress and metabolic reprogramming during liver cancer progression, providing potential therapeutic implications for liver cancer.